Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Takeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., March 03, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX ...